6
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
8
Rare Diseases
across 14 areas
0
News (30d)
Quiet
Biogen Idec, Inc. is a company with 6 orphan drug designations across 8 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell chronic lymphocytic leukemia | anti-CD23 IgG1, kappa monoclonal antibody | Des.TrialAppr. |
| autoimmune thrombocytopenic purpura | toralizumab | Des.TrialAppr. |
| brain cancer | Interferon beta (recombinant human) | Des.TrialAppr. |
| brainstem cancer | Interferon beta (recombinant human) | Des.TrialAppr. |
| idiopathic pulmonary fibrosis | humanized monoclonal antibody against human integrin alphaVbeta6 | Des.TrialAppr. |
| primary brain neoplasm | Interferon beta (recombinant human) | Des.TrialAppr. |
| pulmonary fibrosis | Interferon beta-1a (recombinant human) | Des.TrialAppr. |
| systemic lupus erythematosus | Humanized MAb (IDEC-131) to CD40L | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
19
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
19
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio